Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

PTN vs MBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PTN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 3–6 Matrix Metrics)

PTN Overall Winner 6-Pillar Tally: PTN 3 – 2 MBIO (1 Tie) Matrix Metrics: PTN 3 – 6 MBIO

As of Nov 16, 2026, Palatin Technologies, Inc. (PTN) is the stronger overall head-to-head candidate over Mustang Bio, Inc. (MBIO) in the Tradestie Institutional Equity Comparison Engine, winning 3–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). PTN carries a Unified Composite Score of 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin), whereas MBIO carries 42.9/100 (HOLD) at $0.39 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While MBIO currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. PTN 31.5/100 SELL), PTN captures the overall institutional head-to-head verdict (3–6 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-65.7% vs. 0.0% operating margin) and revenue trajectory (-80.1% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: PTN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9); meanwhile MBIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PTN vs MBIO
PTN US Equity Head-to-Head Winner
Palatin Technologies, Inc.
Pharmaceutical Preparations
$6.12
-1.69% 1D
Market Cap $11.1M
TTM Revenue $13M
Forward P/E 42.9x
Beta / 30D Vol 0.87β · 106% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 15.0 Fund 30.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.5%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $5.72 · SMA50: $8.07
MBIO NASDAQ
Mustang Bio, Inc.
Pharmaceutical Preparations
$0.39
-6.34% 1D
Market Cap $3.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.66β · 86% Vol
Unified Composite Score
42.9 / 100 HOLD
Tech 40.0 Fund 49.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.4 · SMA20: $0.40 · SMA50: $0.44

6-Pillar Scorecard Institutional Category Breakdown (PTN 3 – 2 MBIO)

Columns: Metric · PTN · MBIO
1. Valuation Multiples PTN
Forward P/E 42.9x N/M
Trailing P/E 42.9x N/M
PEG Ratio 1.62x N/M
EV / Revenue 0.1x N/M
2. Growth & Scale MBIO
Revenue Growth (YoY) -80.1% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $13M N/A
Market Cap $11.1M $3.2M
3. Profitability & Quality MBIO
Gross Margin 6.2% N/A
Operating Margin -65.7% 0.0%
Net Profit Margin -63.5% 0.0%
Return on Equity (ROE) -877.5% -43.1%
4. Balance Sheet & Cash Flow PTN
Cash Generation (TTM) -$15M N/A
Cash Flow Margin -113.6% N/A
Net Cash / Leverage $9.9M Net Cash $0.87 Book/Sh · -43.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat PTN
OpEx & R&D Intensity 71.9% of Rev ($9.5M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PTN (3) vs MBIO (6)
Institutional Metric PTN MBIO Criterion Row Edge
Market Capitalization
Scale
$11.1M $3.2M Larger Scale Tie
Trailing P/E Ratio
Valuation
42.9x N/M Lower Multiple PTN
Forward P/E Ratio
Valuation
42.9x N/M Lower Multiple PTN
Revenue Growth (YoY)
Growth
-80.1% +0.0% Higher Growth MBIO
Operating Margin (TTM)
Profitability
-65.7% 0.0% Higher Margin MBIO
Net Profit Margin
Profitability
-63.5% 0.0% Higher Margin MBIO
Return on Equity (ROE)
Capital Efficiency
-877.5% -43.1% Higher ROE MBIO
52-Week Range Position
Momentum
6% ($5–$31) 4% ($0–$1) Stronger Trend PTN
Beta / 30D Volatility
Risk Regime
0.87β · 106% Vol 0.66β · 86% Vol Lower Realized Risk MBIO
Unified Institutional Score
Composite Signal
31.5 / 100 (SELL) 42.9 / 100 (HOLD) Higher Composite MBIO
Trailing 12M Revenue (USD)
Operating Scale
$13M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
6.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.62x PEG · 0.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$15M ($9.9M Net Cash) N/A ($0.87 Book/Sh · -43.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MBIO +3.12 pp
PTN: +1.74% · MBIO: +4.86%
3M Horizon MBIO +10.97 pp
PTN: -41.72% · MBIO: -30.75%
6M Horizon MBIO +25.82 pp
PTN: -59.81% · MBIO: -33.99%
1Y Horizon PTN +24.09 pp
PTN: -43.29% · MBIO: -67.38%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PTN vs MBIO. Trailing 12-month operating profitability (PTN -65.7% vs MBIO 0.0%) and valuation multiples (PTN 42.9x vs MBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PTN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$13M
Gross Margin6.2%
Op. Margin-65.7%
ROE / Fwd P/E-877.5% · 42.9x
MBIO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-43.1% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PTN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PTN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MBIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PTN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $11.1M market capitalization and -65.7% operating margin.
OpEx & R&D Reinvestment 71.9% of Rev ($9.5M)
90D Engineering Disclosures 0 Published
MBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PTN vs MBIO Key Questions & Quantitative Answers

As of Nov 16, 2026, Palatin Technologies, Inc. (PTN) is the stronger overall head-to-head candidate over Mustang Bio, Inc. (MBIO) in the Tradestie Institutional Equity Comparison Engine, winning 3–6 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). PTN carries a Unified Composite Score of 31.5/100 (SELL) at $6.12 (42.9x Forward P/E, -65.7% operating margin), whereas MBIO carries 42.9/100 (HOLD) at $0.39 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MBIO currently prints a higher short-term Unified Composite Score (42.9/100 HOLD vs. PTN 31.5/100 SELL), PTN captures the overall institutional head-to-head verdict (3–6 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-65.7% vs. 0.0% operating margin) and revenue trajectory (-80.1% vs. +0.0% YoY). Technical & Structure Timing Caution: PTN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.9); meanwhile MBIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MBIO leads the Growth & Scale pillar: PTN posts -80.1% YoY revenue growth and +0.0% YoY earnings growth on $13M TTM revenue (6.2% gross margin, -65.7% operating margin), compared with MBIO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PTN generates $13M in USD-normalized revenue versus N/A for MBIO. In operating R&D and SG&A reinvestment, PTN deploys 71.9% of Rev ($9.5M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MBIO.

PTN screens cheaper on headline valuation multiples. PTN trades at 42.9x Forward P/E, 42.9x Trailing P/E, 1.62x PEG, and 0.1x EV/Revenue (-113.6% FCF margin), whereas MBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PTN (-877.5% ROE) versus MBIO (-43.1% ROE) capital efficiency.

In options market volatility and institutional positioning, PTN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.87β · 106% Vol realized risk). By comparison, MBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.66β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.